#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Chemical burn Dilated cardiomyopathy Homocystinuria Nephrotic syndrome Follicle centre lymphoma follicular grade I, II – III Urethral valves Asthma Medulloblastoma Hypochondroplasia White matter lesion Ewing's sarcoma Anal fistula Glioblastoma Superficial vein thrombosis Adenocarcinoma gastric More trials…

    Learn about Rare Diseases

    Vascular malformation – Treatment Hereditary optic atrophy – Diagnostics Proteus syndrome – Trials in Disease Mitochondrial myopathy – Trials in Disease Hereditary neuropathic amyloidosis – Treatment Gaucher’s disease type III – Life with Disease Marginal zone lymphoma – Basic Information Krabbe’s disease – Basic Information Angiosarcoma metastatic – Trials in Disease Advanced systemic mastocytosis – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Naproxen Isoprenaline Hydrochloride Nadroparin Calcium Valoctocogene Roxaparvovec CITRIC ACID ANHYDROUS SONLICROMANOL HYDROCHLORIDE Vortioxetine Hydrobromide Sodium Hypochlorite Ly3556050 Povidone SALICYLIC ACID Tamuzimod Acetate Efgartigimod Alfa Ocrelizumab Caspofungin Toldc Olaparib Finerenone ALN-961583 Masofaniten More therapies…

    Learn about Your Condition

    Cold type haemolytic anaemia Metastases to liver Cardiac failure acute Castleman's disease Abdominal wall pain Death neonatal Renal cancer recurrent Ejection fraction normal Mumps Sarcoma metastatic Post-traumatic headache Herpes simplex reactivation Major depression Tertiary adrenal insufficiency Lymphangioma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Squamous cell carcinoma of head and neck

  • Study of ALE.C04 and Pembrolizumab for Adults with Recurrent or Metastatic Head and Neck Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Ale.c04
    • Pembrolizumab
    France Italy Spain

  • Study of BGB-A425, LBL-007, and Tislelizumab for Patients with Advanced Head and Neck Cancer, Lung Cancer, or Kidney Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Renal cell carcinoma
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Lbl-007
    • Surzebiclimab
    • Tislelizumab
    France Italy Poland Spain

  • Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Cisplatin
    • Pembrolizumab
    Austria Belgium France Germany Hungary Ireland +3

  • Study on Radiotherapy with Xevinapant or Placebo for Older Patients with Advanced Head and Neck Cancer

    Not recruiting

    2 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Xevinapant
    Belgium France Germany Ireland Italy The Netherlands +3

  • Study of IO102-IO103 and Pembrolizumab for Patients with Resectable Melanoma and Head and Neck Squamous Cell Carcinoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Malignant melanoma
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Io103 Acetate
    • Pembrolizumab
    Denmark France Germany Spain

  • Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Human Igg1K Monoclonal Antibody Against Tim-3
    • Retifanlimab
    • Tuparstobart
    France Greece Italy Portugal Spain
Previous Page
1 … 9 10 11 12
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!